StockNews.com initiated coverage on shares of Adaptimmune Therapeutics ( NASDAQ:ADAP – Free Report ) in a report published on Thursday. The firm issued a hold rating on the biotechnology company's stock. ADAP has been the topic of a number of other reports. Barclays cut their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.00 and set an underweight rating on the stock in a research report on Thursday, August 10th. Guggenheim lowered their target price on Adaptimmune Therapeutics from $5.

https://www.dailypolitical.com/2023/10/08/adaptimmune-therapeutics-nasdaqadap-earns-hold-rating-from-analysts-at-stocknews-com.html

#dailypolitical